Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This is a study to assess the safety of the combination of mifepristone and eribulin in
patients with metastatic or locally advanced unresectable breast or other specified solid
tumors, and determine preliminary efficacy of the combination of mifepristone and eribulin in
patients with metastatic or locally advanced unresectable Triple Negative Breast Cancer
(TNBC). The structure for the study is a single arm, non-randomized, open-label, multicenter
trial with no control group. The study will be conducted at up to 11 sites, with up to 40
evaluable patients